Disease · MONDO_0021063
Comparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 14 of 14
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Capecitabine vs 5-Fluorouracil + Leucovorin: Relapse-Free Survival | 677 of 1,004 | 621 of 983 | 1,987 | NCT00009737 | Trial comparisons |
| Capecitabine vs 5-Fluorouracil + Leucovorin: Disease-free Survival | 656 of 1,004 | 603 of 983 | 1,987 | NCT00009737 | Trial comparisons |
| Capecitabine vs 5-Fluorouracil + Leucovorin: Overall Survival | 804 of 1,004 | 756 of 983 | 1,987 | NCT00009737 | Trial comparisons |
| Capecitabine vs 5-Fluorouracil + Leucovorin: serious adverse events | 181 of 995 | 182 of 974 | 1,969 | NCT00009737 | Trial comparisons |
| Arm I (Blood Stored and Tested for ctDNA Later) vs Arm II (Blood Tested for ctDNA at Baseline): deaths from any cause | 8 of 318 | 6 of 317 | 635 | NCT04068103 | Trial comparisons |
| BBI608 vs Placebo: Disease Control Rate | 17 of 138 | 18 of 144 | 282 | NCT01830621 | Trial comparisons |
| BBI608 vs Placebo: Number of Patients With Adverse Events | 135 of 136 | 139 of 144 | 280 | NCT01830621 | Trial comparisons |
| BBI608 vs Placebo: deaths from any cause | 127 of 136 | 130 of 144 | 280 | NCT01830621 | Trial comparisons |
| BBI608 vs Placebo: serious adverse events | 40 of 136 | 29 of 144 | 280 | NCT01830621 | Trial comparisons |
| XELOX + Bevacizumab vs XELIRI + Bevacizumab: Number of Participants With Serious Adverse Events (SAEs) | 9 of 34 | 11 of 31 | 65 | NCT00127036 | Trial comparisons |
| XELOX + Bevacizumab vs XELIRI + Bevacizumab: serious adverse events | 9 of 34 | 11 of 31 | 65 | NCT00127036 | Trial comparisons |
Head and Neck vs Colon- Closed as of May 2014: Response Rate (Whether Patient's Disease is Progressing or Being Controlled) of Patients With Head and Neck Cancer Treated With Eribulin Mesylate and Cetuximab. | 6 of 8 | 2 of 15 | 23 | NCT01744340 | Trial comparisons |
| Head and Neck vs Colon- Closed as of May 2014: serious adverse events | 5 of 8 | 1 of 15 | 23 | NCT01744340 | Trial comparisons |
Head and Neck vs Colon- Closed as of May 2014: If Eribulin Mesylate, up to a Maximum Dose of 1.4 mg/m2 Day 1 and 8 of a 21 Day Cycle, Can be Safely Combined With Full Dose Cetuximab for Patients With Advanced Head and Neck Cancer and Colon Cancer. | 0 of 1 | 0 of 5 | 6 | NCT01744340 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021063/comparisons